Clinical Trial Detail

NCT ID NCT03299088
Title Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of California, Davis
Indications

lung non-small cell carcinoma

Therapies

Pembrolizumab + Trametinib

Age Groups: adult senior

No variant requirements are available.